Competition
Competition - Who Can Hurt MOH and Who It Can Beat
Competitive Bottom Line
Molina has a real but narrow moat: incumbency at state Medicaid agencies plus a best-in-class government-only cost structure, producing a 90% re-procurement renewal rate on $14B of revenue at risk and a roughly 6.4% adjusted G&A ratio — the lowest in the public peer group. That advantage is concentrated in one product (Medicaid) and is structurally narrower than the vertically integrated giants' moats: UnitedHealth, CVS/Aetna, and Elevance earn margin in three pools (premium + PBM + care delivery) and Molina earns it in one. The single competitor that matters most is Centene (CNC) — the named primary competitor in both Medicaid and Marketplace, ~2.7x Molina's Medicaid membership (12.5M vs 4.6M), with the dominant Ambetter Marketplace book (5.5M members vs MOH's shrinking 655k) and the deeper acquired-state distribution of Wellcare in Medicare. Molina can defend its lane; it cannot expand it without buying scale.
Bottom line. The moat is real where Molina chooses to fight (Medicaid incumbency, RFP execution, low G&A) and absent where it doesn't (PBM rebate spread, care-delivery margin, commercial diversification). The 2025 collapse is a rate-lag artifact, not a moat break — but the post-OBBBA addressable Medicaid pool is permanently smaller, which means the same moat protects a smaller premium pool by 2029.
The Right Peer Set
Molina's FY2025 10-K Item 1 names the primary-competitor universe by segment. The same five names are used here because (a) the company defines them as primaries, (b) every one competes head-to-head with Molina in at least one of the three product lines, and (c) the set spans the two structural archetypes that matter for moat judgment: pure-play government specialists (CNC) and vertically integrated multi-line giants (UNH, CVS, ELV, HUM). All are NYSE-listed US-domiciled USD reporters.
MOH EV is artificially low because Yahoo treats $8.3B of regulated subsidiary investments as cash; the relevant comparison is on revenue and ROE, not EV.
Peers split into two clusters. CNC and MOH sit in the "government-program specialist" zone (Medicaid >55% of revenue). Everyone else treats Medicaid as a sleeve, not the franchise. MOH is the smallest member of the specialist cluster and the only one without a PBM or care-delivery arm.
Where The Company Wins
Three measurable dimensions, all direct consequences of being a pure-play government MCO.
1. G&A discipline — the only margin lever an MCO truly controls
A 6.4% adjusted G&A ratio (FY2026 guide; FY2025 actual was 6.5%) is the lowest in the public peer set. The gap is structural: Molina has no commercial book to underwrite, no PBM platform to operate, and no care-delivery footprint to manage. It bids the lowest cost structure into Medicaid procurements and accepts that it will never own the rest of the value chain. At parity MCR, MOH wins on price.
2. RFP execution — incumbency that compounds
State Medicaid agencies evaluate bids on clinical model, claims-payment reliability, provider-network depth, and incumbency. Molina's 90% renewal rate compounds: every incumbent term locks in 3-5 years of fixed revenue and improves the next bid's win probability via member-experience scoring. The Mississippi transition is the cleanest 2025 read on the moat: Molina took over from UnitedHealthcare effective 6/30/2025 — the largest MCO in the country was outbid by the smallest public one.
3. Quality accreditation density
4. Cycle-tested ROE
In the depth of the rate-trend dislocation, Molina's trough ROE of 11.0% sits ahead of every other pure-play and integrated peer except the two diversified giants (ELV, UNH). Centene — the cleanest economic comp — booked a $6.4B net loss. Molina's pricing discipline (it cut Marketplace 50% rather than chase share) is the cause.
Where Competitors Are Better
Four dimensions of durable structural disadvantage.
1. Vertical integration — UNH, CVS, ELV earn margin in pools MOH cannot reach
This is the structural valuation gap. UNH trades at ~0.87x EV/Revenue and CVS at ~0.47x because their revenue dollars carry multiple margin claims. Molina trades at 0.09x because every revenue dollar is single-margin Medicaid premium with a minimum-MLR floor that caps the upside. No amount of operating excellence closes that gap without acquiring or building a PBM/services arm — neither is on Molina's roadmap.
2. Medicare Advantage — MOH is sub-scale and shrinking
Molina is the smallest MA operator in the peer set by ~5x (vs HUM) to ~32x (vs UNH). The MAPD exit concedes the segment. The pivot to dual-eligible (D-SNP) integrated plans plays to Molina's Medicaid franchise, but the addressable market is materially smaller than open MA, and Humana, CVS/Aetna, and UNH all run D-SNP books with full clinical and prescription drug integration that Molina cannot match without a PBM partner.
3. Marketplace — Centene's Ambetter is the franchise
Marketplace is structurally Centene's market. Molina's 2024-25 strategy (aggressive growth into a deteriorating risk pool) backfired and forced the 50% retrenchment. CNC managed the same cycle without ceding share. Marketplace is a margin-recovery exit for MOH, not a contestable share-shift opportunity.
4. State concentration / single-customer risk
The Washington contract has been renewed only through 12/31/2026 with a 2026 RFP planned for January 2028 start — the single largest re-procurement event on the horizon.
Threat Map
The Centene rivalry is the single most important competitive fact. Centene is the named primary competitor in two of Molina's three product lines, runs at ~4x Molina's revenue, owns the Marketplace franchise outright with 5.5M Ambetter members across 29 states, and serves 2.7x more Medicaid members. CNC's FY2025 net loss ($6.4B) is a near-term opportunity — a wounded rival is a wounded bidder — but CNC has no exit plan and is rebuilding under new leadership. The two will compete head-to-head in every Medicaid procurement through the late-2020s, and Molina's Medicaid growth target of 11-13% can only be hit by taking share from CNC or by acquiring smaller plans.
Moat Watchpoints
The signals below tell you whether Molina's competitive position is improving, holding, or deteriorating. They are observable in public disclosures on a known calendar.
The cleanest single test of moat direction is RFP win/loss cadence in MOH's top-10 state contracts over rolling 24-month windows. Everything else — MCR, G&A, Star Ratings, even share count — is a financial output that confirms or denies a more fundamental question: are state Medicaid agencies still choosing Molina at re-procurement? The 2017 trough briefly saw that answer become "no" (Florida loss + others); the 2018-2024 recovery was the answer flipping back to "yes". Virginia was a single "no". One more is noise within statistical bounds; two more is a reset.